Edap Tms Launches Focal One i to Address Rising Prostate Cancer Demand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy EDAP?
Source: Yahoo Finance
- Growing Market Demand: EDAP highlights the rising global demand for HIFU, positioning its newly launched Focal One i as a first-line treatment for prostate cancer, supported by over 1,000 publications and large clinical trials demonstrating its advantages in treatment efficacy and functional outcomes.
- Favorable Reimbursement Policies: Medicare claims for HIFU have shown exponential growth from 2022 to 2024, with a January payment change increasing APC6/CPT 55880 reimbursement by approximately 4.3%, which not only narrows the gap to surgeon payments but also facilitates widespread adoption of Focal One systems in the U.S. and Europe.
- Strengthened Clinical Evidence: Launched in April 2025, Focal One i features enhanced fusion capabilities and AI tool integration, supporting multiple imaging inputs, while clinical studies indicate that HIFU outperforms traditional surgery in cancer control, urinary continence, and sexual function, further solidifying its market position.
- New Market Expansion: EDAP is advancing studies for benign prostatic hyperplasia (BPH) with plans to treat patients at an IRB-approved U.S. academic site, while also initiating a limited launch in Europe for deep infiltrating endometriosis, showcasing the company's potential for expansion across multiple therapeutic areas.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EDAP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EDAP
Wall Street analysts forecast EDAP stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.730
Low
2.50
Averages
8.25
High
14.00
Current: 3.730
Low
2.50
Averages
8.25
High
14.00
About EDAP
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EDAP Reports 39% Revenue Growth in HIFU for 2025
- HIFU Revenue Growth: EDAP achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by strong demand in the U.S. market, demonstrating the company's market penetration capabilities in high-growth sectors.
- Global Sales Milestone: In Q4 2025, EDAP recorded 15 Focal One device placements worldwide, with 14 being cash sales, marking a robust performance in equipment sales and further solidifying its market leadership position.
- Financial Challenges: Despite the growth in HIFU revenue, total revenue for 2025 was EUR 62.4 million, a 3% decline year-over-year, primarily due to a 27% drop in non-core distribution and ESWL businesses, which poses pressure on the company's overall financial health.
- Future Outlook: The company expects HIFU revenue in 2026 to range from USD 50 million to USD 54 million, representing a growth of 34% to 45%, and plans to transition to a new ultrasound engine to mitigate tariff impacts, thereby enhancing margins and competitive positioning.
See More
EDAP TMS S.A. Reports Record Q4 2025 Earnings Growth
- Core Business Growth: EDAP TMS achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by accelerated adoption in the U.S., marking a strong performance in the rapidly growing medical device market.
- Record Quarter: Q4 2025 HIFU revenue was EUR 11.7 million, a 34% increase year-over-year, making it the strongest quarter in the company's history, indicating sustained growth potential in the medical technology sector.
- International Market Expansion: The company recorded first-time sales in India and Argentina, along with additional system sales in Italy and Spain, further solidifying its global footprint and highlighting EDAP TMS's strategic focus on emerging markets.
- Outlook: Management expects core HIFU revenue to range between USD 50 million and USD 54 million in 2026, representing a 34% to 45% growth, demonstrating confidence in future growth driven by ongoing investments in technology innovation and market execution.
See More
EDAP TMS S.A. Q4 Earnings Report Analysis
- Earnings Performance: EDAP TMS S.A. reported a Q4 GAAP EPS of -$0.25, missing expectations by $0.10, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Growth: Total revenue for Q4 reached $21.88 million, up 0.4% year-over-year, with HIFU business revenue at €11.7 million ($13.5 million), reflecting a robust 34% increase compared to the same period in 2024, showcasing strong core business performance.
- Decline in Non-Core Business: Revenue from non-core businesses (ESWL and Distribution) fell to €7.2 million ($8.4 million) in Q4, down from €11.5 million ($12.3 million) in 2024, highlighting increased market competition and weakened demand.
- 2026 Financial Guidance: The company reiterated its 2026 revenue guidance of $72.0 million to $80.0 million, with core HIFU business expected to generate between $50.0 million and $54.0 million, indicating confidence in future growth, though market conditions remain a concern.
See More
EDAP Reports Record HIFU Revenue Growth in 2025
- Significant Revenue Growth: EDAP's HIFU business achieved total revenue of €33.1 million ($37.4 million) in 2025, reflecting a 39% year-over-year increase, indicating strong market demand for non-invasive treatment options.
- Record System Sales: In Q4 2025, the company sold 14 Focal One systems, marking a quarterly sales record that underscores the increasing focus of urologists in the U.S. on treating early-stage prostate cancer.
- Sustained Procedure Growth: Focal One procedures in the U.S. grew by 28% year-over-year in Q4 2025, representing the second consecutive quarter of double-digit growth, which highlights the growing acceptance of this technology in the market.
- Optimistic Future Outlook: The company reiterated its 2026 revenue guidance, expecting HIFU revenue to grow between 34% and 45%, reflecting confidence in future market potential, particularly with rising demand from large healthcare networks for multiple system purchases.
See More
EDAP TMS S.A. to Announce Q4 Earnings on March 25
- Earnings Announcement Date: EDAP TMS S.A. is set to release its Q4 2023 earnings on March 25 before the market opens, with consensus EPS estimate at -$0.15 and revenue forecast at $21.28 million, indicating ongoing challenges in profitability.
- Historical Performance Review: Over the past year, EDAP has only beaten EPS estimates 25% of the time and revenue estimates 25% of the time, reflecting difficulties in managing market expectations effectively.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates saw two upward revisions and no downward adjustments, suggesting increased market confidence in future revenue.
- Quant Rating Insights: Seeking Alpha's Quant Rating on EDAP TMS S.A. provides investors with critical decision-making information based on financial data and historical performance, despite the current low earnings expectations.
See More
Edap Tms Launches Focal One i to Address Rising Prostate Cancer Demand
- Growing Market Demand: EDAP highlights the rising global demand for HIFU, positioning its newly launched Focal One i as a first-line treatment for prostate cancer, supported by over 1,000 publications and large clinical trials demonstrating its advantages in treatment efficacy and functional outcomes.
- Favorable Reimbursement Policies: Medicare claims for HIFU have shown exponential growth from 2022 to 2024, with a January payment change increasing APC6/CPT 55880 reimbursement by approximately 4.3%, which not only narrows the gap to surgeon payments but also facilitates widespread adoption of Focal One systems in the U.S. and Europe.
- Strengthened Clinical Evidence: Launched in April 2025, Focal One i features enhanced fusion capabilities and AI tool integration, supporting multiple imaging inputs, while clinical studies indicate that HIFU outperforms traditional surgery in cancer control, urinary continence, and sexual function, further solidifying its market position.
- New Market Expansion: EDAP is advancing studies for benign prostatic hyperplasia (BPH) with plans to treat patients at an IRB-approved U.S. academic site, while also initiating a limited launch in Europe for deep infiltrating endometriosis, showcasing the company's potential for expansion across multiple therapeutic areas.
See More
EDAP Reports 39% Revenue Growth in HIFU for 2025
- HIFU Revenue Growth: EDAP achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by strong demand in the U.S. market, demonstrating the company's market penetration capabilities in high-growth sectors.
- Global Sales Milestone: In Q4 2025, EDAP recorded 15 Focal One device placements worldwide, with 14 being cash sales, marking a robust performance in equipment sales and further solidifying its market leadership position.
- Financial Challenges: Despite the growth in HIFU revenue, total revenue for 2025 was EUR 62.4 million, a 3% decline year-over-year, primarily due to a 27% drop in non-core distribution and ESWL businesses, which poses pressure on the company's overall financial health.
- Future Outlook: The company expects HIFU revenue in 2026 to range from USD 50 million to USD 54 million, representing a growth of 34% to 45%, and plans to transition to a new ultrasound engine to mitigate tariff impacts, thereby enhancing margins and competitive positioning.
See More
EDAP TMS S.A. Reports Record Q4 2025 Earnings Growth
- Core Business Growth: EDAP TMS achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by accelerated adoption in the U.S., marking a strong performance in the rapidly growing medical device market.
- Record Quarter: Q4 2025 HIFU revenue was EUR 11.7 million, a 34% increase year-over-year, making it the strongest quarter in the company's history, indicating sustained growth potential in the medical technology sector.
- International Market Expansion: The company recorded first-time sales in India and Argentina, along with additional system sales in Italy and Spain, further solidifying its global footprint and highlighting EDAP TMS's strategic focus on emerging markets.
- Outlook: Management expects core HIFU revenue to range between USD 50 million and USD 54 million in 2026, representing a 34% to 45% growth, demonstrating confidence in future growth driven by ongoing investments in technology innovation and market execution.
See More
EDAP TMS S.A. Q4 Earnings Report Analysis
- Earnings Performance: EDAP TMS S.A. reported a Q4 GAAP EPS of -$0.25, missing expectations by $0.10, indicating challenges in profitability that could negatively impact investor confidence.
- Revenue Growth: Total revenue for Q4 reached $21.88 million, up 0.4% year-over-year, with HIFU business revenue at €11.7 million ($13.5 million), reflecting a robust 34% increase compared to the same period in 2024, showcasing strong core business performance.
- Decline in Non-Core Business: Revenue from non-core businesses (ESWL and Distribution) fell to €7.2 million ($8.4 million) in Q4, down from €11.5 million ($12.3 million) in 2024, highlighting increased market competition and weakened demand.
- 2026 Financial Guidance: The company reiterated its 2026 revenue guidance of $72.0 million to $80.0 million, with core HIFU business expected to generate between $50.0 million and $54.0 million, indicating confidence in future growth, though market conditions remain a concern.
See More
EDAP Reports Record HIFU Revenue Growth in 2025
- Significant Revenue Growth: EDAP's HIFU business achieved total revenue of €33.1 million ($37.4 million) in 2025, reflecting a 39% year-over-year increase, indicating strong market demand for non-invasive treatment options.
- Record System Sales: In Q4 2025, the company sold 14 Focal One systems, marking a quarterly sales record that underscores the increasing focus of urologists in the U.S. on treating early-stage prostate cancer.
- Sustained Procedure Growth: Focal One procedures in the U.S. grew by 28% year-over-year in Q4 2025, representing the second consecutive quarter of double-digit growth, which highlights the growing acceptance of this technology in the market.
- Optimistic Future Outlook: The company reiterated its 2026 revenue guidance, expecting HIFU revenue to grow between 34% and 45%, reflecting confidence in future market potential, particularly with rising demand from large healthcare networks for multiple system purchases.
See More
EDAP TMS S.A. to Announce Q4 Earnings on March 25
- Earnings Announcement Date: EDAP TMS S.A. is set to release its Q4 2023 earnings on March 25 before the market opens, with consensus EPS estimate at -$0.15 and revenue forecast at $21.28 million, indicating ongoing challenges in profitability.
- Historical Performance Review: Over the past year, EDAP has only beaten EPS estimates 25% of the time and revenue estimates 25% of the time, reflecting difficulties in managing market expectations effectively.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates saw two upward revisions and no downward adjustments, suggesting increased market confidence in future revenue.
- Quant Rating Insights: Seeking Alpha's Quant Rating on EDAP TMS S.A. provides investors with critical decision-making information based on financial data and historical performance, despite the current low earnings expectations.
See More
Edap Tms Launches Focal One i to Address Rising Prostate Cancer Demand
- Growing Market Demand: EDAP highlights the rising global demand for HIFU, positioning its newly launched Focal One i as a first-line treatment for prostate cancer, supported by over 1,000 publications and large clinical trials demonstrating its advantages in treatment efficacy and functional outcomes.
- Favorable Reimbursement Policies: Medicare claims for HIFU have shown exponential growth from 2022 to 2024, with a January payment change increasing APC6/CPT 55880 reimbursement by approximately 4.3%, which not only narrows the gap to surgeon payments but also facilitates widespread adoption of Focal One systems in the U.S. and Europe.
- Strengthened Clinical Evidence: Launched in April 2025, Focal One i features enhanced fusion capabilities and AI tool integration, supporting multiple imaging inputs, while clinical studies indicate that HIFU outperforms traditional surgery in cancer control, urinary continence, and sexual function, further solidifying its market position.
- New Market Expansion: EDAP is advancing studies for benign prostatic hyperplasia (BPH) with plans to treat patients at an IRB-approved U.S. academic site, while also initiating a limited launch in Europe for deep infiltrating endometriosis, showcasing the company's potential for expansion across multiple therapeutic areas.
See More
